RPI ID: 2024-015-301
Innovation Summary: This technology introduces a point-of-care diagnostic system for urinary biomarkers using ultrasensitive ImmunoMag-CRISPR lateral flow assays. It combines magnetic bead-based sample preparation with CRISPR-based detection for enhanced sensitivity and specificity. The system is portable and designed for rapid, on-site testing in clinical and remote settings.
Challenges / Opportunities: Current biomarker testing methods often require centralized labs and long turnaround times. This invention addresses the need for decentralized, rapid diagnostics. It opens opportunities for early disease detection and monitoring in low-resource environments.
Key Benefits / Advantages: ✔ High sensitivity and specificity ✔ Portable and rapid testing ✔ Combines magnetic and CRISPR technologies ✔ Suitable for clinical and field use
Applications: • Point-of-care diagnostics for urinary biomarkers
Keywords: CRISPR diagnostics, lateral flow assay, urinary biomarkers, point-of-care testing, ImmunoMag
Intellectual Property: WO2025085888A1 (Application PCT/US2024/052198), Published October 21, 2024